News Sentiment

CTXR sentiment intelligence

Citius Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 68 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.50 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-14.9% over one week, -9.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -14.9% Price reacting lower
Trend fit Trend inactive -9.3% over four weeks
Fair value -94.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 49
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
PR Newswire 11
TradingView 11
Market source 10
TradingKey 6
Stock Titan 4
Simply Wall Street 2
Moomoo 2
GuruFocus 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 21
Analyst action 8
Deals and strategy 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 68
Quartr Direct company coverage

Citius Oncology (CTOR) Registration filing Summary

Citius Oncology (CTOR) focuses on developing targeted oncology therapies, with its lead product LYMPHIR, approved by the FDA in August 2024 and launched in December 2025. The company became public via a reverse merger in August 2024. Recent financial activities include offerings

Tone
Neutral 50/100
Event
Deals and strategy
Published
16 Jul 2026 03:41
Source
Quartr
TradingView Direct company coverage

Enterprise value to revenue forward of Citius Pharmaceuticals Inc – LS:A40MD0

This article provides financial information for Citius Pharmaceuticals Inc (LS:A40MD0) on TradingView, specifically focusing on its enterprise value to revenue forward. It appears to be a stub or data-centric page within a larger financial platform, offering no descriptive text b

Tone
Neutral 50/100
Event
Earnings
Published
11 Jul 2026 10:41
Source
TradingView
AD HOC NEWS Direct company coverage

Citius Pharmaceuticals updates pipeline as investors track CTXR stock

Citius Pharmaceuticals is advancing its specialty pharmaceutical pipeline, with its CTXR stock attracting investor attention due to its focus on critical care and oncology support. As a development-stage company, CTXR's valuation is highly sensitive to clinical progress, regulato

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 19:12
Source
AD HOC NEWS
Insider Financial Direct company coverage

Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is A Biotech Runner: Here's Why

Citius Pharmaceuticals Inc (CTXR) is highlighted as a biotech opportunity due to operational developments not yet reflected in its share price. The company has two main assets: Mino-Lok, a treatment for catheter-related blood stream infections, and Hydro-Lido, a pharmaceutical-gr

Tone
Positive 67/100
Event
Market update
Published
02 Jul 2026 23:40
Source
Insider Financial
TradingView Direct company coverage

Enterprise value to EBIT forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR

This article provides financial data for Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), specifically focusing on its enterprise value to EBIT forward. The content appears to be a direct data output from TradingView, displaying key financial metrics without further analysis or textua

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 11:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Citius Pharmaceuticals, Inc. – NASDAQ:CTXR

This article displays the "Price to earnings forward" financial metric for Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) on TradingView. It presents financial overview information related to the company's stock performance. The content is primarily a listing within the TradingView

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 17:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR

This article focuses on the enterprise value to revenue forward for Citius Pharmaceuticals, Inc. (CTXR). It appears to be a financial snapshot or data point from TradingView, highlighting a specific metric for the company. The content shown is primarily navigational and introduct

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR

The article provides a financial glance at Citius Pharmaceuticals, Inc. (CTXR) focusing on its Enterprise Value to EBIT forward metric. It appears to be a snapshot from a financial data platform like TradingView, indicating that the market was closed at the time of publication an

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 04:10
Source
TradingView
TradingView Direct company coverage

Citius Pharmaceuticals Inc Actuals & Estimates (NASDAQ:CTXR)

This article provides an overview of Citius Pharmaceuticals Inc. (CTXR) stock performance, financial data, and analyst estimates. Key information includes its current stock price, recent price changes, analyst forecasts, historical highs and lows, market capitalization, upcoming

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 19:10
Source
TradingView
TradingView Direct company coverage

47N0 Forecast — Price Target — Prediction for 2027

This article provides a forecast for Citius Pharmaceuticals Inc (47N0) stock, indicating a 1-year price target of 3.44 EUR from one analyst. It details the company's financial metrics, including past earnings and revenue, and key information like its next earnings date (August 17

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 14:41
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Citius Pharmaceuticals, Inc. – BOATS:CTXR

The article displays the "Price to sales forward" metric for Citius Pharmaceuticals, Inc. (CTXR) within the TradingView platform. It provides a snapshot of the company's financial data under the "Blue Ocean Alternative Trade System" (BOATS) and indicates that the market is curren

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 13:41
Source
TradingView
TradingView Direct company coverage

CTXR Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Citius Pharmaceuticals, Inc. (CTXR) stock for 2027 based on analyst opinions. It includes financial data, stock performance, market capitalization, earnings reports, and historical price information, highlighting a 1-year pric

Tone
Negative 33/100
Event
Analyst action
Published
25 Jun 2026 13:41
Source
TradingView
TradingKey Direct company coverage

Citius Pharmaceuticals Inc (CTXR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Citius Pharmaceuticals Inc (CTXR), highlighting its current earnings forecast score, average price target, and expected revenue and EPS for upcoming periods. It details analyst predictions for the stock's price, revenue, and earnings

Tone
Positive 71/100
Event
Earnings
Published
18 Jun 2026 17:41
Source
TradingKey
TradingKey Direct company coverage

Citius Pharmaceuticals Inc (CTXR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of Citius Pharmaceuticals Inc (CTXR) shareholder structure, detailing major individual and institutional shareholders. It presents data on the proportion of shares held by various entities and shareholder types, along with historical institutiona

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 05:40
Source
TradingKey
TradingKey Direct company coverage

Citius Pharmaceuticals Inc (CTXR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Citius Pharmaceuticals Inc (CTXR) stock information, including its current dividend history and stock split data. The company has not distributed dividends in the past five years, but it has several upcoming stock merger events scheduled for N

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 01:40
Source
TradingKey
TradingKey Direct company coverage

Citius Pharmaceuticals Inc (CTXR) Institutional Confidence

This article from TradingKey provides an overview of Citius Pharmaceuticals Inc (CTXR)'s institutional confidence score and related shareholder activity. It details the shares held by various institutional investors and the percentage change in their holdings. The report highligh

Tone
Positive 61/100
Event
Market update
Published
17 Jun 2026 04:39
Source
TradingKey
TradingKey Direct company coverage

Citius Pharmaceuticals Inc (CTXR) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Citius Pharmaceuticals Inc (CTXR), revealing a current financial score of 7.91, ranking 72 out of 388 in the Biotechnology & Medical Research industry. The company's financial status is described as weak, though its operating e

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 03:39
Source
TradingKey
TradingKey Direct company coverage

Citius Pharmaceuticals Inc (CTXR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Citius Pharmaceuticals Inc (CTXR), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of June 16, 2026, CTXR's price momentum score is 2.04, placing it low within it

Tone
Negative 30/100
Event
Market update
Published
17 Jun 2026 03:39
Source
TradingKey
Simply Wall Street Direct company coverage

Citius Pharmaceuticals (Nasdaq:CTXR) - Stock Analysis

This article provides a stock analysis of Citius Pharmaceuticals (Nasdaq:CTXR), highlighting its current market capitalization, analyst price target indicating it's undervalued, and projected earnings growth. It also delves into various risks, including share price volatility, sh

Tone
Negative 30/100
Event
Analyst action
Published
04 Jun 2026 11:40
Source
Simply Wall Street
Finviz Direct company coverage

CTXR - Citius Pharmaceuticals Inc Stock Price and Quote

This article provides a detailed stock overview for Citius Pharmaceuticals Inc (CTXR), including its current stock price, financial metrics, and recent news. It highlights the company's focus on critical care products, particularly in oncology and anti-infectives, and lists signi

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 23:40
Source
Finviz
Stock Titan Direct company coverage

[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing

This SEC filing for Citius Pharmaceuticals, Inc. (CTXR) is an "EFFECT" filing, indicating a Notice of Effectiveness for an S-3 form with an effective date of June 2, 2026, at 4:15 P.M. The filing detail includes the company's CIK and file number. The impact and sentiment of this

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 10:10
Source
Stock Titan
MarketBeat Direct company coverage

Citius Pharmaceuticals (CTXR) 10K Form and Latest SEC Filings 2026

MarketBeat provides an overview of Citius Pharmaceuticals' (CTXR) SEC filings, including its 10K forms, 10Q reports, and 8K current reports. The article details how investors can use these publicly available documents to evaluate the company's financial health, with the most rece

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 23:10
Source
MarketBeat
Stock Titan Direct company coverage

Citius Oncology (NASDAQ: CTXR) shares early Phase 1 LYMPHIR cancer data

Citius Oncology (NASDAQ: CTXR) announced early Phase 1 data for LYMPHIR (denileukin diftitox-cxdl) combined with pembrolizumab in recurrent or refractory gynecologic cancers. The study, involving 21 efficacy-evaluable patients, showed a 48% clinical benefit rate and a median prog

Tone
Positive 67/100
Event
Market update
Published
01 Jun 2026 20:40
Source
Stock Titan